OncoMatch/Clinical Trials/NCT07037680
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Is NCT07037680 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Anlotinib for locally advanced non-small cell lung cancer.
Treatment: Anlotinib — Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic chemotherapy
Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression
Cannot have received: thoracic radiotherapy
thoracic radiotherapy history ... within three months
Lab requirements
Kidney function
adequate renal function with a negative urine protein
Liver function
adequate hepatic function
Adequate hepatic and renal functions with a negative urine protein
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07037680 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thoracic radiotherapy disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages